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introduction: The functional capacity of the testes in prepubertal boys with cryptor-
chidism before treatment has received very little attention. The assessment of testicular 
function at diagnosis could be helpful in the understanding of the pathophysiology of 
cryptorchidism and in the evaluation of the effect of treatment. Anti-Müllerian hormone 
is a well-accepted Sertoli cell biomarker to evaluate testicular function during childhood 
without the need for stimulation tests.
Objective: The aim of the study was to assess testicular function in prepubertal children 
with cryptorchidism before orchiopexy, by determining serum anti-Müllerian hormone 
(AMH). We also evaluated serum gonadotropins and testosterone and looked for asso-
ciations between testicular function and the clinical characteristics of cryptorchidism.
Materials and methods: We performed a retrospective, cross-sectional, analytical 
study at a tertiary pediatric public hospital. All clinical charts of patients admitted at the 
outpatient clinic, and recorded in our database with the diagnosis of cryptorchidism, 
were eligible. The main outcome measure of the study was the serum concentration 
of AMH. Secondary outcome measures were serum LH, FSH, and testosterone. For 
comparison, serum hormone levels from a normal population of 179 apparently normal 
prepubertal boys were used.
results: Out of 1,557 patients eligible in our database, 186 with bilateral and 124 with 
unilateral cryptorchidism were selected using a randomization software. Median AMH 
standard deviation score was below 0 in both the bilaterally and the unilaterally crypt-
orchid groups, indicating that testicular function was overall decreased in patients with 
cryptorchidism. Serum AMH was significantly lower in boys with bilateral cryptorchidism 
as compared with controls and unilaterally cryptorchid patients between 6 months and 
1.9 years and between 2 and 8.9 years of age. Serum AMH below the normal range 
reflected testicular dysfunction in 9.5–36.5% of patients according to the age group in 
bilaterally cryptorchid boys and 6.3–16.7% in unilaterally cryptorchid boys. FSH was ele-
vated in 8.1% and LH in 9.1% of boys with bilateral cryptorchidism, most of whom were 
anorchid. In patients with present testes, gonadotropins were only mildly elevated in less 
than 5% of the cases. Basal testosterone was mildly decreased in patients younger than 
6 months old, and uninformative during childhood.
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conclusion: Prepubertal boys with cryptorchidism, especially those with bilaterally 
undescended gonads, have decreased AMH production. Although serum AMH may 
fall within the normal range, there is a considerable prevalence of testicular dysfunction 
during childhood in this frequent condition.
Keywords: anti-Müllerian hormone, gonadotropins, hypogonadism, sertoli cells, testosterone, undescended 
testes
inTrODUcTiOn
Cryptorchidism is one of the most frequent congenital malforma-
tions in the male, with a prevalence at birth ranging from 1.6 to 
5.7% (1–4), and up to 9% in Denmark (5). In patients with a his-
tory of cryptorchidism, the risk for infertility (6–8) and testicular 
cancer (7, 9) is highly increased.
Cryptorchidism is the consequence of the lack or insufficiency 
of the process of testicular descent taking place during fetal life. 
The testes are initially formed near the kidneys and descend fol-
lowing a two-phase process (10); in the first phase, between the 
8th and 15th fetal weeks, the testes are anchored to the internal 
inguinal ring by the gubernaculum. A Leydig cell factor named 
insulin-like 3 (INSL3) and its receptor RXFP2 are major regulators 
of gubernacular development (11). In addition, the androgen-
regulated regression of the testicular cranial suspensory ligament 
also seems to play a role (12). Anti-Müllerian hormone (AMH) 
has also been suggested to participate, although this remains 
controversial (13). In the second phase, the testes migrate from 
the internal inguinal ring to the scrotum, mainly driven by the 
effect of androgens and intra-abdominal pressure (14). This phase 
is usually completed in humans by the time of birth; therefore, 
prematurity is associated with a higher incidence of cryptorchid-
ism (5). Spontaneous descent may still occur in the first months of 
postnatal life (4, 5), and re-ascent can occur later in life probably 
associated with the development of the cremasteric reflex and 
the existence of a remnant of the processus vaginalis preventing 
normal elongation of the spermatic cord, leading to the concept 
of acquired cryptorchidism (4, 15).
While a large bibliography exists on the controversies regard-
ing the most adequate treatment for cryptorchidism and its 
timeliness (16, 17), it is surprising that less attention has been 
given to the functional capacity of the prepubertal testes before 
treatment. It is clear that cryptorchidism may be a sign of several 
conditions with different underlying pathogeneses (7). In the 
vast majority of the cases, the sign is treated—i.e., the abnormal 
position is repaired—without knowing the degree of affectation 
of the gonadal axis. Assessing testicular function at the time of 
diagnosis may help in the understanding of the pathophysiology 
of cryptorchidism in each patient and in the ensuing evaluation 
of the effect of treatment.
Because the hypothalamic–pituitary–gonadal axis undergoes 
a relative quiescence after the age of 6 months and during child-
hood (18, 19), classical markers like testosterone and gonadotro-
pins are of little use in the assessment of testicular function in 
the prepubertal boy. Conversely, Sertoli cells maintain an active 
secretory activity and serum levels of Sertoli cell biomarkers like 
AMH (20–22) and inhibin B (21, 23, 24), can readily inform 
about testicular function without the need for stimulation tests. 
Indeed, undetectable serum AMH is clearly more robust than 
testosterone post-hCG to diagnose or rule out anorchidism in 
boys with non-palpable gonads (25). AMH is secreted exclusively 
by the Sertoli cells of the testis in males, from early fetal life (26) 
where it is involved in male sex differentiation by inducing the 
regression of the Müllerian ducts, i.e., the anlagen of the uterus 
and Fallopian tubes. Although this process is completed in the 
first trimester of the fetal period, Sertoli cells continue to secrete 
high amounts during infancy and childhood. Testicular AMH 
production varies with age; therefore, the normal reference 
ranges of serum AMH levels change during postnatal develop-
ment (27–29).
The aim of this study was to assess testicular function in 
prepubertal children with cryptorchidism before orchiopexy, by 
determining the serum concentration of AMH. Secondarily, we 
evaluated the serum concentrations of gonadotropins and testos-
terone and looked for associations between testicular function 
and the clinical characteristics of cryptorchidism.
sUBJecTs anD MeThODs
study Design and setting
We performed a retrospective, cross-sectional, analytical study 
at the Division of Endocrinology of the Ricardo Gutiérrez 
Children’s Hospital, a tertiary pediatric public hospital in Buenos 
Aires, Argentina.
The same pediatric endocrinologist performed a careful 
review of clinical charts. Clinical description of cryptorchidism 
as unilateral and bilateral, testicular volume measured by com-
parison to Prader’s orchidometer, position of the gonads, pubic 
hair, and genital development according to Marshall and Tanner 
(30), and of the presence of hernia or micropenis were extracted 
from the history chart. Patients’ personal history data, including 
gestational age and birth weight, history of hCG treatments, and 
orchiopexy were registered. Hormonal values were extracted 
from the history chart and the laboratory Cobas® Infinity system 
(Roche).
Patients
Patients With Cryptorchidism
All clinical charts of subjects admitted at the outpatient clinic 
of the Division of Endocrinology of the Ricardo Gutiérrez 
Children’s Hospital between 2000 and 2017, and recorded in 
our database with the diagnosis of cryptorchidism, were eligible. 
Cryptorchidism was defined by the absence of one or both testes 
in the scrotum. Inclusion criteria were the presence of cryptor-
chidism, normal virilization (urethral orifice at the end of the 
penis and complete fusion of the scrotum) and the availability of 
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a result of serum AMH determination performed before orchi-
opexy at a prepubertal stage, defined by testicular volume ≤ 3 ml 
as compared with Prader’s orchidometer and according to Tanner 
stages. The following exclusion criteria applied: history chart 
absent or incomplete, a diagnosis of disorders of sex develop-
ment or genetic syndromes known to affect testicular function, 
genital, or abdominal–pelvic surgeries susceptible of affecting the 
gonadal vessels performed before the first hormonal evaluation, 
radiotherapy, or chemotherapy.
Healthy Controls
For comparison, we used serum levels of AMH, testosterone, 
FSH, and LH from a sample of 179 apparently normal prepubertal 
boys, which have been published previously (29). This cohort 
fulfilled the following criteria: (i) written informed consent 
was given by the participant’s parents, (ii) a blood sample was 
being drawn for routine clinical evaluation independently of 
the research study, (iii) anamnesis ruled out cryptorchidism or 
other genital or urologic malformations, endocrine diseases, and 
chronic or acute general pathologies that could affect endocrine 
function, and (iv) a clinical examination was performed to assess 
Tanner pubertal stage and to determine testicular position and 
volume by comparison with Prader’s orchidometer.
Outcome Measures and Definitions
The main outcome measure of the study was the serum con-
centration of AMH. Secondary outcome measures were serum 
concentrations of LH, FSH, and testosterone. Circulating levels 
of reproductive hormones were compared between patients with 
cryptorchidism and normal boys. Serum AMH and FSH were, 
respectively, used as a direct and an indirect biomarker of the 
functional mass of prepubertal Sertoli cells (21), whereas serum 
testosterone and LH were, respectively, used as a direct and an 
indirect biomarker of Leydig cells. All data were obtained at first 
referral, before any hormonal or surgical treatment was attempted. 
In a small subset of patients, a second assessment was available 
after orchiopexy in these cases, a longitudinal comparison (at 
referral vs after surgery) was made.
For the primary analysis, patients with cryptorchidism 
and controls were grouped by age intervals (all prepubertal). 
Subsequent stratification for subgroup analysis was done accord-
ing to the clinical characteristics of the cryptorchidism, such as 
palpability and position of the testes. According to the AMH val-
ues, patients were classified as functionally anorchid when serum 
AMH was non-detectable, hypogonadal when serum AMH was 
detectable but below the normal reference level (below the 3rd 
percentile for age), and eugonadal when serum AMH was within 
the normal reference level.
Other potentially associated variables considered in this study 
were as follows: gestational age at birth, birth weight, penile size, 
presence of inguinal hernia, and hCG treatment for cryptor-
chidism. Gestational age was a dichotomic variable (preterm/
full-term), considering preterm birth when gestational age was 
<37 weeks. Birth weight was analyzed as a continuous variable. 
Weight for gestational age was a dichotomic variable (small 
for gestational age/adequate for gestational age), considering 
small for gestational age when weight was <3rd percentile for 
gestational age according to local references (31). Penile size was 
dichotomized (micropenis/normal), and micropenis was defined 
by penile size < −2 SD according to the Argentine references for 
age (32). Presence of inguinal hernia was dichotomized (yes/no), 
according to the attending physician’s description in the clinical 
chart. Treatment with hCG followed a standardized protocol used 
at the Division of Endocrinology, consisting of 1,000 IU of hCG 
administered IM once weekly for 5 weeks, and assessment within 
1 month following the last injection. Treatment was considered 
successful if the gonad was in the scrotum at physical examina-
tion, and unsuccessful if it was not in scrotal position.
study size
The sample size was calculated for the main outcome measure, 
i.e., the prevalence of hypogonadism (patients with serum AMH 
below the normal reference range) in prepubertal patients with 
cryptorchidism. The estimated study size required 181 patients 
with bilateral cryptorchidism and 116 patients with unilateral 
cryptorchidism, to detect a prevalence of hypogonadism of 36 
and 18%, respectively, based on previously unpublished own 
studies, with an accuracy of 7% and a confidence level of 95%.
hormone assays
Anti-Müllerian Hormone
Results of serum AMH determinations were all obtained with 
an enzyme-linked immunoassay specific for human AMH (EIA 
AMH/MIS®, Beckman-Coulter Co., Marseilles, France), as 
previously validated by our group (29, 33). Intra- and inter-assay 
coefficients of variation were, respectively, 10.5 and 9.4%, for a 
serum AMH concentration of 700 pmol/L, and 11.1 and 12.8% 
for a serum AMH concentration of 7 pmol/L. When serum AMH 
levels were undetectable, the value of the limit of quantification 
(functional sensitivity = 2.5 pmol/L) was attributed.
Gonadotropins
LH and FSH were determined using electrochemiluminescent 
immunoassays (ECLIAs, Roche Diagnostics GmbH, Mannheim, 
Germany) as described (33). The limits of quantification of both 
LH and FSH assays were 0.10 IU/L, according to the 2nd NIBSC 
IS 80/552 for LH and the 2nd WHO IRP 78/549 for FSH. Intra- 
and inter-assay coefficients of variation were 1.1 and 1.8% for LH, 
respectively, for a mean LH concentration of 2.8  IU/L and 1.4 
and 1.5% for a mean LH concentration of 16.9 IU/L. Intra- and 
inter-assay coefficients of variation were 1.0 and 4.2% for FSH, 
respectively, for a mean FSH concentration of 14.8 IU/L and 1.1 
and 4.1% for a mean FSH concentration of 23.4  IU/L. When 
serum LH or FSH levels were undetectable, the value of the limit 
of quantification (functional sensitivity) was attributed.
Testosterone
Testosterone was determined in serum using an ECLIA (Roche 
Diagnostics GmbH, Mannheim, Germany) as described (29). 
Intra- and inter-assay coefficients of variation were 2.4 and 2.6%, 
respectively, for a mean testosterone concentration of 176 ng/dL 
(6.10 nmol/L) and 1.2 and 2.3% for a mean testosterone concen-
tration of 455 ng/dL (15.78 nmol/L). When serum testosterone 
FigUre 1 | Flowchart of patient inclusion in the study.
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levels were undetectable, the value of the limit of quantification 
(functional sensitivity = 10 ng/dL) was attributed.
statistical analyses
Because serum AMH varies with age in normal boys during 
infancy and childhood, values were analyzed using the standard 
deviation score (SDS) for age in the overall evaluation. In the 
age subgroup analyses, absolute serum levels and percentiles 
were used. Data distribution was assessed for normality using 
the Shapiro–Wilk test. Results are expressed as median and 
range. Because non-Gaussian distribution was found in most 
cases, non-parametric tests were used for comparisons. The 
Wilcoxon Signed Rank Test was used to compare median SDS 
with the theoretical value of 0 SDS. Mann–Whitney test was used 
to compare serum hormone levels between two independent 
groups. Kruskal–Wallis test with Dunn’s multiple comparison 
posttest was used when more than two groups were compared. 
Fisher’s exact test was used to compare categorical variables. 
Logistic regression was performed to analyze potential risk fac-
tors associated with decreased AMH, considered as a categorical 
variable (serum AMH below the 3rd percentile for age). The level 
of significance was set at P < 0.05. All statistical analyses were 
performed using GraphPad Prism version 7.03 for Windows 
(GraphPad Software, San Diego, CA, USA) and STATA 13 
(StataCorp LLC, College Station, TX, USA).
resUlTs
characteristics of the study Population
Our database contained 1,557 patients with “cryptorchidism” as 
a diagnosis (524 bilateral and 1,033 unilateral cryptorchidism). 
Filtering the database for lack of clinical chart number, history of 
genital or abdominal surgery and for other exclusion diagnoses 
(see Subjects and Methods), a total of 178 cases were excluded, 
leaving 393 cases of bilateral and 986 cases of unilateral cryptor-
chidism as eligible for our study. Using a randomization software, 
we selected and reviewed 390 clinical charts (240 with bilateral 
and 150 with unilateral cryptorchidism). Eighty (54 with bilateral 
and 26 with unilateral cryptorchidism) were discarded because the 
history chart was incomplete, the diagnosis was not cryptorchid-
ism (database recording error), there was a history of genital or 
abdominal surgery or of chemotherapy or radiotherapy reported 
in the chart, a result of a serum AMH measurement was not avail-
able in the prepubertal period, or other exclusion diagnoses were 
found in the chart. Finally, 310 patients with cryptorchidism, 186 
with bilateral cryptorchidism, and 124 with unilateral (50% right 
cryptorchidism) were analyzed in the study (Figure 1).
Median age at first hormonal evaluation was approximately 
3 years, with a wide range (Table 1). The proportion of patients 
born preterm, with micropenis or hernia, or having received hCG 
treatment for cryptorchidism varied according to the age groups. 
Only two preterm patients were born at <28 weeks.
anti-Müllerian hormone
Median AMH SDS was below 0 in both the bilaterally (Wilcoxon 
signed rank test, P < 0.0001) and the unilaterally (P = 0.0052) 
cryptorchid groups (Figure 2), indicating that testicular function 
is overall decreased in patients with cryptorchidism. Testicular 
function was more affected in the bilaterally than in the unilater-
ally cryptorchid group (Mann–Whitney test, P < 0.0001). In the 
bilaterally cryptorchid boys, serum AMH was below 0 SDS in 
80.1% of the cases; furthermore, it was below −1 SDS in 39.8% of 
the cases. In the unilateral cryptorchidism group, the impairment 
was milder, with only 62.9% of the patients with serum AMH 
below 0 SDS.
To assess testicular function specifically in patients with uni-
lateral or bilateral cryptorchidism according to age, we analyzed 
absolute serum AMH levels and the percentile distribution. 
In patients with bilateral cryptorchidism, serum AMH was 
undetectable—thus indicative of anorchidism—in nine cases 
(Figure  3A). This represents 4.8% of all patients with bilateral 
cryptorchidism and 26.5% of those with non-palpable gonads. 
Patients with anorchidism were excluded from all the subsequent 
comparisons of testicular function between groups. Serum AMH 
concentration of boys with bilateral cryptorchidism was signifi-
cantly lower than in the control and the unilaterally cryptorchid 
groups between 6  months and 1.9  years and between 2 and 
8.9 years of age (Table 2).
The prevalence of serum AMH below the normal range 
(<3rd percentile) indicated an increased proportion of patients 
with hypogonadism in all age groups, even in those groups 
with a normal median serum AMH (Table 2). The prevalence 
of AMH below the normal range was greater in patients with 
bilateral cryptorchidism than in boys with unilateral cryptor-
chidism between 6 months and 1.9 years (Fisher’s exact test, 
P = 0.006) and in boys between 2 and 8.9 years (Fisher’s exact 
test, P =  0.043). In fact, AMH was below the normal range 
in 16.6% of the whole group of patients with cryptorchidism 
and present gonads, 22.6% of boys with bilateral cryptorchid-
ism and 8.1% of boys with unilateral cryptorchidism. These 
results showed only minor changes when patients with central 
hypogonadism were excluded (Table S1 in Supplementary 
Material).
FigUre 2 | Serum levels of anti-Müllerian hormone (AMH), expressed as 
standard deviation score (SDS) for age, in patients with unilateral or bilateral 
cryptorchidism. Bars indicate medians and interquartile ranges.
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Testicular function was not worse in patients with bilaterally 
non-palpable gonads, as compared with patients with bilateral 
cryptorchidism and at least one palpable gonad (Fisher’s exact 
test, P = 0.45). Median serum AMH was not significantly differ-
ent in any of the age groups (Table 3).
To identify risk factors for hypogonadism (AMH levels < 3rd 
percentile) in cryptorchid boys, we performed a logistic regres-
sion (Table 4). The factors that were significantly associated with 
AMH levels < 3rd percentile were bilateral cryptorchidism, as 
compared with unilateral cryptorchidism, and the presence of 
micropenis. Sixteen out of 17 boys (94.2%) with micropenis 
had AMH levels below the normal range (Figure 3A; Table 5). 
One patient was anorchid (undetectable AMH) and five 
of them were diagnosed with central hypogonadism (data 
obtained from clinical charts reporting testosterone treatment 
at age ≥14 years). There were no significant differences in the 
prevalence of hypogonadism (AMH < 3rd percentile) between 
preterm and full-term patients, either in the total group or in 
patients with unilateral or bilateral cryptorchidism (Table 6). 
Likewise, serum AMH did not differ significantly between 
preterm and full-term cryptorchid patients (Mann–Whitney 
test, P = 0.275; Figure 4A). We hypothesized that, in patients 
with hernia, testicular maldescent would be the result of an 
anatomical hindrance rather than a testicular dysfunction. 
However, the prevalence of hypogonadism was not signifi-
cantly lower than that observed in patients with cryptorchid 
gonads not associated with an inguinal hernia (Table 6). Also, 
no difference was found in serum AMH between cryptorchid 
patients with or without inguinal hernia (Mann–Whitney test, 
P = 0.288; Figure 4B).
Treatment with hCG for cryptorchidism was performed 
in 132 of 310 (42.6%) patients according to local standard 
procedures. Treatment was performed in 43 of the 124 (34.7%) 
patients with unilateral cryptorchidism, with a success rate of 
FigUre 3 | Hormone serum levels in cryptorchid boys: (a) anti-Müllerian hormone (AMH), (B) testosterone, (c) FSH, and (D) LH. Empty circles indicate cryptorchid 
boys with micropenis, stars indicate anorchid boys, and triangles indicate anorchid boys with micropenis. Abbreviations: Ctrl, normal controls; Uni, unilateral 
cryptorchidism; BI, bilateral cryptorchidism.
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20.9%. AMH levels did not differ significantly between patients 
in whom hCG treatment was successful or unsuccessful 
(Mann–Whitney test, P = 0.581; Figure 5A). In the group of 
bilaterally cryptorchid boys, 89 of 186 (47.9%) received hCG 
with a success rate of 28.1% for the descent of both testes and 
15.7% for one testis. AMH levels of bilaterally cryptorchid boys 
who showed a successful response of both testes to hCG were 
higher than those of boys with no response (Kruskal–Wallis 
test followed by Dunn’s Multiple Comparison Test, P = 0.0001; 
Figure 5B).
Orchiopexy was performed in 151 patients. Serum AMH levels 
were available in 76 patients at referral, i.e., before any treatment 
was attempted, and at least 1 month after surgery. A statistically 
significant increase was observed in AMH levels after orchiopexy 
(Paired T test, P = 0.0030, Figure 6).
Testosterone
In patients aged 1–5.9  months, lower testosterone levels were 
observed in the unilaterally cryptorchid group as compared 
with controls (Kruskal–Wallis test followed by Dunn’s Multiple 
Comparison Test, P = 0.029; Figure 3B). During the rest of child-
hood, testosterone levels are usually very low or undetectable in 
normal boys. Accordingly, serum testosterone was below the limit 
of detection of the assay (10  ng/dL) in 265 of 276 cryptorchid 
patients aged >6  months; in the remaining 11 patients, serum 
testosterone ranged between 11 and 75  ng/dL. Therefore, no 
statistical comparisons were made between groups.
gonadotropins
Serum gonadotropin levels were within the normal range in the 
vast majority of patients with unilateral or bilateral cryptorchid-
ism independent of age (Figures  3C,D). Only 4 of 124 (3.2%) 
boys with unilateral cryptorchidism had elevated FSH (>97th 
percentile for age), between 2.7 and 6.2 IU/L. In boys with bilat-
eral cryptorchidism, FSH was elevated in 15 of 186 (8.1%) cases. 
Eight of them proved to be anorchid, with FSH levels ranging 
from 7 to 200 IU/L. In the remaining seven cases, FSH was mildly 
elevated, between 2 and 7.3 IU/L.
Serum LH was elevated (>97th percentile for age), between 
0.2 and 8.9 IU/L, in 9 of 124 (7.3%) boys with unilateral cryptor-
chidism, and in 17 of 186 (9.1%) boys with bilateral cryptorchid-
ism (Figure 3). Seven of the latter were anorchid, with LH levels 
ranging from 0.25 to 67.1 IU/L. In the remaining 10 cases, LH was 
mildly elevated, between 0.2 and 12.2 IU/L.
When the subgroup of patients with abnormally low AMH 
(<3rd percentile for age) was analyzed, 13 of 59 (22.0%) had 
elevated FSH for age, 8 of whom were anorchid. In the 51 cryp-
torchid patients with bilaterally present gonads, elevated FSH was 
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observed in only 5 cases (9.8%). Serum LH was elevated in 9 of 
the 59 patients (15.3%), and in only 2 (3.9%) of the boys with 
present testes.
DiscUssiOn
Controversial results on whether testicular AMH production is 
decreased in prepubertal boys with cryptorchidism have been 
reported in a few studies with small number of patients of a large 
range of ages and including cases of both unilateral and bilateral 
cryptorchidism (25, 34–38) (Table 7). Our study including 310 
prepubertal patients randomly selected from a cohort of more 
than 1,500 boys with cryptorchidism shows that, as a group, 
cryptorchid patients have lower AMH production than normal 
boys. Even though most of cryptorchid patients have serum 
AMH levels within the reference range, there is a considerable 
prevalence of cases with abnormally decreased serum AMH, 
indicating an affected testicular function during childhood. 
The prevalence of testicular dysfunction did not increase with 
age. As could be expected, low serum AMH concentration 
was found more often in patients with bilateral than unilateral 
cryptorchidism.
With the aim of evaluating the pituitary–testicular axis in 
patients with cryptorchidism, serum levels of another Sertoli cell 
marker—inhibin B—and of Leydig cell markers—testosterone 
and INSL3—have also been assessed in different studies. INSL3, 
but not the other markers, has consistently been found low in 
cord blood from cryptorchid newborns (47, 48). Basal testos-
terone and INSL3 are no longer informative in childhood after 
postnatal activation wanes at 3–6  months of age, since their 
circulating levels are very low or undetectable. Like AMH, inhi-
bin B also shows controversial results in boys with cryptorchid-
ism. However, most studies indicate that there is an increased 
prevalence of patients with low basal inhibin B or inhibin B/
FSH ratio in older infants and children with cryptorchidism 
(38, 44, 49–51). Altogether, these results and our present data 
using basal AMH as a Sertoli cell marker suggest that there is 
an increased risk of seminiferous tubule dysfunction already 
in childhood even though the gonadotropin axis is relatively 
quiescent. Furthermore, lower levels of inhibin B have been 
shown to correlate with decreased number of spermatogonia in 
infancy (50, 52), a predictor of infertility in males with a history 
cryptorchidism (53–56).
In our large cohort of cryptorchid boys, the median SDS for 
serum AMH was below 0 both in the unilaterally and bilaterally 
cryptorchid groups, which indicates that the testicular Sertoli 
cell compartment is overall affected. Serum AMH levels found 
in patients with bilateral cryptorchidism were clustered in the 
lowest ranges: indeed, 39.8% of the values were below 1 SDS, 
as compared with 15.9% expected according to a Gaussian dis-
tribution. Furthermore, more than one-fifth of patients with 
bilateral cryptorchidism had overtly abnormal serum AMH, 
i.e., levels below the 3rd percentile for age, thus validating the 
prevalence of childhood hypogonadism previously reported in 
a smaller series of cryptorchid boys (38). Other studies report 
mean serum AMH levels but do not discriminate the percent-
age of patients with abnormally low AMH production (34, 35, 
TaBle 4 | Logistic regression performed to identify potential risk factors for 
hypogonadism (AMH levels < 3rd percentile) in boys with cryptorchidism 
(unilateral and bilateral considered together).
Odds ratio 95% ci P
Bilateral cryptorchidism 3.63 1.52–8.66 0.004
Micropenis 91.70 10.96–767.05 <0.001
Hernia 1.41 0.60–3.3327 0.430
Preterm 0.81 0.27–2.41 0.705
Birth weight 0.99 0.99–1.00 0.389
SGA 0.54 0.15–1.91 0.339
Age at evaluation 1.02 0.91–1.14 0.748
CI, confidence interval; AMH, anti-Müllerian hormone; SGA, small for gestational age.
TaBle 3 | Serum anti-Müllerian hormone (AMH) in bilaterally cryptorchid boys with non-palpable gonads and boys with at least one palpable gonad.
1–5.9 months 6 months–1.9 years 2–8.9 years ≥9 years
non-
palpable 
gonads
at least one 
palpable 
gonad
non-palpable 
gonads
at least one 
palpable gonad
non-
palpable 
gonads
at least one 
palpable gonad
non-palpable 
gonads
at least one 
palpable gonad
n 1 6 9 43 12 85 3 18
Median (pmol/L) 1,269 993 530 574 498 535 260 593
Range (pmol/L) N.A. 153–1,417 277–1,003 34–1,747 35–938 31–1,400 43–835 178–1,175
Mann–Whitney test N.A. a a a a a a
N.A., not applicable.
To obtain serum AMH in ng/mL, divide by 7.14.
Mann–Whitney test (“Non-palpable gonads” vs “At least one palpable gonad”): same letter indicates lack of significant difference (P > 0.05).
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37, 44). When analyzed by age groups, we found a prevalence 
of hypogonadism—as indicated by AMH < 3rd percentile—
in 36.5% of the patients between 6  months and 2  years, an 
age at which most cryptorchid patients are referred to the 
pediatric endocrinologist. In our series, recruited between 
2000 and 2017, we have noticed a high frequency of relatively 
late referral, with a predominance after 2 years of age, which 
raises the concern of a potential progressive testicular damage 
until the time of treatment (57–59). However, the proportion 
of bilaterally cryptorchid patients with impaired Sertoli cell 
function was not higher in the 2- to 9-year-old group than in 
the younger group. Furthermore, no influence of age at first 
hormonal evaluation (always performed before treatment in 
our series) was found on the prevalence of impaired Sertoli 
cell function as determined by serum AMH < 3rd percentile, 
in agreement with other observational studies indicating no 
progressive damage associated with delayed orchiopexy (57, 
60–62). The latter studies clearly identified that there are at 
least two conditions in patients with cryptorchidism: in one, 
testes are already affected at early infancy, showing absence 
of spermatogonia type Ad, and in the other, testes have Ad 
spermatogonia. After long-term follow-up until adulthood, 
patients who had Ad spermatogonia at biopsy during orchi-
opexy were fertile with normal spermiograms in contrast 
to those with absence of Ad spermatogonia, who showed 
abnormal spermiograms, regardless of the age at orchiopexy 
(57). Nonetheless, it should be emphasized that our study was 
not designed to assess the effect of early vs late treatment on 
testicular function, and definitive results of long-term pro-
spective clinical trials will certainly shed light on this concern 
(58, 63). Another limitation of our study is linked with the 
relatively small number of patients of the two extreme age 
groups, which may result in low power to detect decreased 
AMH or increased prevalence of Sertoli cell dysfunction with 
enough statistical significance.
In the unilateral cryptorchidism group, the impairment was 
milder, with only 62.9% of the patients with serum AMH below 
0 SDS and less than 10% of patients with AMH below the 3rd 
percentile. These results confirm results of a recent study compar-
ing serum AMH between unilaterally cryptorchid patients and 
normal boys (40), and are in line with the observation in a large 
scale, long-term follow-up study, that unsuccessful paternity was 
10.3% in patients with a history of unilateral cryptorchidism and 
6.8% in controls (64).
With the aim of identifying risk factors associated with 
Sertoli cell dysfunction in patients with cryptorchidism, in 
addition to the previously discussed bilaterality, logistic regres-
sion analysis detected micropenis with a very high odds ratio. A 
limitation of our study, related to its retrospective design, is that 
certain recently detected genetic, maternal, and environmental 
risk factors (65) were not screened by the attending clinician. 
The occurrence of micropenis at birth is indicative of insuf-
ficient androgen exposure during the second half of fetal life 
(66), which can be due to fetal testicular regression syndrome 
resulting in congenital anorchidism. This was the case in one 
patient with non-palpable gonads of our cohort, in whom the 
finding of undetectable AMH in serum lead to early diagnosis 
of anorchidism. More frequently, congenital micropenis is 
associated with central (hypogonadotropic) hypogonadism. In 
these cases, the low levels of AMH are the consequence of insuf-
ficient FSH in intrauterine life resulting in decreased number of 
Sertoli cells and impaired AMH gene expression in each Sertoli 
cell (67–69).
Excluding anorchid patients, the majority of whom showed 
very high gonadotropin levels, only a very low proportion of 
prepubertal cryptorchid boys had a mild elevation of serum 
gonadotropins, even in the case of patients with manifest primary 
hypogonadism as revealed by abnormally low serum AMH levels, 
thus emphasizing that primary hypogonadism is rarely hyper-
gonadotropic in prepubertal patients (33, 70, 71).
The pathogenesis of cryptorchidism may involve disorders of 
the hypothalamic–pituitary–gonadal axis or anatomical defects 
with no primary endocrine deficiency. In central or primary 
TaBle 6 | Prevalence of patients with hypogonadism (anti-Müllerian hormone 
levels < 3rd percentile) according to prematurity and the presence of hernia in 
cryptorchid boys.
Preterm Term Pa hernia no 
hernia
Pa
All, n (%) 10 (27.8) 39 (15.4) 0.093 11 (17.5) 48 (19.4) 0.858
Unilateral 
cryptorchidism, 
n (%)
2 (18.2) 8 (7.3) 0.303 2 (6.3) 8 (8.7) 1.000
Bilateral 
cryptorchidism, 
n (%)
8 (32.0) 31 (22.0) 0.229 9 (28.0) 40 (26.0) 0.826
aFisher’s exact test, “Preterm” vs “Term” or “Hernia” vs “No hernia.”
TaBle 5 | Serum hormone levels in cryptorchid boys with micropenis.
1–5.9 months 6 months–1.9 years 2–8.9 years ≥9 years
aMha
n 3 5 8 1
Median (pmol/L) 153 53 79 147
Range (pmol/L) N.D.–226 34–321 31–525 N.A.
<3rd percentile, n (%) 3 (100.0) 5 (100.0) 7 (87.5) 1 (100.0)
Anorchia 1 0 0 0
Bilateral/unilateral 2/1 5/0 8/0 0/1
Fsh
n 3 5 8 1
Median (IU/L) 0.73 0.94 0.45 0.41
Range (IU/L) 0.27–200 0.42–2.4 0.10–0.74 N.A.
>97th percentile, n (%) 1 (33.3) 1 (20.0) 0 0
lh
n 3 5 8 1
Median (IU/L) 0.1 0.1 0.1 0.1
Range (IU/L) 0.10–67.09 0.1–1.5 0.10–0.10 N.A.
>97th percentile, n (%) 1 (33.3) 1 (20.0) 0 0
N.A., not applicable.
aTo obtain serum AMH in ng/mL, divide by 7.14.
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hypogonadism, low testosterone and/or INSL3 are responsible 
for the testicular maldescent. In anatomical defects, like an ingui-
nal hernia, the obstruction of the inguinal canal may preclude 
the normal gonad from completing its descent to the scrotum. 
Therefore, we hypothesized that AMH would not be affected 
in cryptorchid patients with inguinal hernia. However, when 
comparing between patients with and patients without inguinal 
hernia, we did not find a significant difference in serum AMH 
levels, or in the prevalence of patients with evident Sertoli cell 
dysfunction (AMH <  3rd percentile). A possible explanation 
is that the abnormal testicular position per  se would affect the 
Sertoli cell population, independent of the pathogenic mecha-
nism underlying cryptorchidism.
The overtly low AMH levels detected in a subset of patients 
with cryptorchidism could be associated with one or more pos-
sibilities. One is that fetal testicular development is primarily 
defective, and low AMH behaves as a biomarker. Evidence 
for a primary testicular defect arises from large association 
studies showing that reproductive conditions observed at 
birth, like cryptorchidism and hypospadias, and in adults, 
e.g., low sperm counts and testicular cancer, are increasing 
in incidence concomitantly, and are signs of the so-called 
testicular dysgenesis syndrome (72). Furthermore, the risk 
of testicular cancer in patients with a history of unilateral 
cryptorchidism is increased in both testes, indicating that in 
addition to the ectopic position of the testis, there are other 
preexisting factors involved in the mechanism underlying 
the association between cryptorchidism and testicular cancer 
(73). Another possibility is that the abnormal position of the 
testes impairs Sertoli cell development. Normally, Sertoli cells 
proliferate during the postnatal activation of the gonadal axis 
(74) resulting in a mild but significant increase in testicular 
volume (75, 76) and serum AMH (27–29). Conversely, in 
cryptorchid boys the increase in Sertoli cell number (58, 77) 
and testicular volume (58) is impaired. The increase in serum 
AMH levels after orchiopexy observed in our study suggests 
that testicular damage might be at least partially reversible. 
Finally, decreased AMH has been postulated as one etiologic 
factor for cryptorchidism.
In fact, in addition to testosterone and INSL3, AMH has 
been proposed to be involved in testicular descent on the basis 
of observations made in patients with persistent Müllerian 
duct syndrome (PMDS) due to mutations in the genes coding 
for either AMH or its specific receptor AMHR2, although an 
experimental proof-of-concept is still lacking (13). Because the 
testes remain in ovarian position in approximately 40% of PMDS 
boys (78), AMH was initially thought to be involved in the first 
(transabdominal) phase of testicular descent as a candidate to 
stimulate the swelling reaction in the gubernaculum (79), until 
INSL3 was discovered as the factor controlling gubernaculum 
shortening (80). Furthermore, normal testicular descent was 
observed in mice with an experimental knockout of the Amh (81) 
or the Amhr2 (82) gene and in male pups of a female rabbit with 
high levels of blocking anti-AMH antibodies (83). Altogether, 
these observations favored the hypothesis that cryptorchidism 
in PMDS patients is related to the anatomical attachment of 
FigUre 6 | Serum levels of anti-Müllerian hormone (AMH), expressed as 
standard deviation score (SDS) for age, at referral and at least 1 month after 
orchidopexy in patients with cryptorchidism (unilateral or bilateral).
FigUre 5 | Serum levels of anti-Müllerian hormone (AMH), expressed as standard deviation score (SDS) for age, in patients who received hCG treatment for 
cryptorchidism. (a) Unilateral cryptorchidism. (B) Bilateral cryptorchidism. Successful indicates that the testis was in scrotal position at physical examination in the 
visit following hCG treatment.
FigUre 4 | Serum levels of anti-Müllerian hormone (AMH), expressed as standard deviation score (SDS) for age, in preterm or full-term patients with unilateral or 
bilateral cryptorchidism (a) and in unilaterally and bilaterally cryptorchid patients with or without hernia (B). Bars indicate medians and interquartile ranges.
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the testes to the broad ligaments of the persistent uterus (78). 
However, there are anatomical differences that exist between 
humans and mammalian species used as experimental models 
(13), and two anatomical forms responsible for about 60% of 
PMDS cases, presenting either with unilateral cryptorchid-
ism where either one testis in inguinal position along with its 
attached tube and uterus (known as hernia uteri inguinalis) or 
with both testes and Müllerian derivatives herniated on the same 
side (known as transverse testicular ectopia), show an abnormally 
long gubernaculum. These observations, consistent with a role for 
AMH gubernacular shrinkage, have led the hypothesis that AMH 
may increase INSL3 action on the gubernaculum by stimulating 
the shortening of the gubernacular cord (13). This hypothesis 
needs experimental evidence. Our observational study design 
was not conceived to address the potential implication of AMH 
in testicular descent in the largely most frequent cases of cryptor-
chidism, i.e., non-PMDS patients.
The choice between surgical and hormonal treatment for 
cryptorchidism has raised controversies in the last decade (84, 
85), that go beyond the scope of this work. A meta-analysis 
demonstrated that the lower the original position of the testis, 
the better the effect of the hormonal treatment, thus sug-
gesting that LHRH or hCG can be tried in the treatment of 
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inguinal or high scrotal position (86). In our series of patients 
with bilateral cryptorchidism, serum AMH concentration 
was higher in those with a bilaterally successful testicular 
descent in response to a 5-week hCG treatment protocol than 
in those with no response. These results are in line with the 
concordance observed between serum AMH and testosterone 
concentrations during hCG stimulation in boys undergoing 
gonadal function assessment (87), and suggest that basal AMH 
determination may serve as predictive marker of response to 
hCG treatment, in addition to testicular position.
The large sample size of cryptorchid patients included in this 
study and the randomized method used to select cases from a 
database of more than 1,500 potentially eligible patients is one 
major strength of this work. We acknowledge the existence 
of the possibility of a selection bias related to the fact that our 
study was performed in the endocrinology service of a tertiary 
hospital. Cryptorchidism is a condition traditionally treated by 
surgeons. However, the rate of referral of cryptorchid patients 
to the endocrine unit is high in our hospital, due to the mul-
tidisciplinary approach that has been implemented in the last 
two decades and deems endocrine assessment as essential in the 
management of patients with cryptorchidism. The relatively low 
number of patients in the 1–5.9 and >9 years precluded certain 
analyses with the desired power, yet reflect that a low number of 
patients are referred in the first months of life, awaiting a potential 
spontaneous descent (1, 4, 5, 88) but that most are referred before 
pubertal onset, as expected.
Our study included patients over a period of 18 years (years 
2000 through 2017) but had a cross-sectional design, which 
precluded us from performing longitudinal analyses. Another 
concern that may arise from such a long study whose main 
outcome measure derives essentially from AMH determination 
is related to changes in the hormone assay methodology. Because 
we were involved in the development of the commercial AMH/
MIS Beckman-Immunotech assay [usually referred to as IOT (89, 
90)], we have been able to use the same assay all through this 
study. The applicability of our results is assured, even though the 
IOT assay is no longer available, because results of serum AMH 
in the male range are comparable with those obtained with the 
newly developed AMH assays (91).
In conclusion, the population of prepubertal boys with 
cryptorchidism have lower AMH production than normal boys, 
especially those with bilaterally undescended gonads. This could 
be the result of a decreased number of Sertoli cells in the cryp-
torchid gonads and/or to an impaired AMH secretion by each 
Sertoli cell. Although cryptorchid boys may have serum AMH 
within the normal range, our results in a large cohort, together 
with those previously reported in smaller studies, indicate that 
there is a considerable prevalence of testicular dysfunction 
during childhood in this frequent condition. The proportions 
of unilaterally or bilaterally cryptorchid patients with decreased 
AMH in our study are consistent with the risk of azoospermia in 
adulthood (45). However, to know whether Sertoli cell dysfunc-
tion early in life underlies germ cell failure in adulthood will 
need longitudinal follow-up for many years.
eThics sTaTeMenT
The study protocol was approved by the Institutional Review 
Board (Comité de Docencia e Investigación) and Ethics 
Committee (Comité de Ética en Investigación) of the Buenos 
Aires Children’s Hospital (Hospital de Niños Ricardo Gutiérrez 
de Buenos Aires). Because the study of patients with cryptor-
chidism was based on a retrospective clinical chart review with 
TaBle 7 | Comparison between this work and previously published articles reporting on AMH serum or expression levels in boys with cryptorchidism.
reference sample 
size
Population age Unilateral/bilateral 
cryptorchidism
aMh serum or testicular expression levels
Present work 310 Argentine 0.03–13.6 years 
(prepubertal)
124 unilateral and 186 bilateral Decreased in 22.6% of boys with bilateral and 8.1% of boys with unilateral 
cryptorchidism
(39) 156 USA 1 day–20 years 16 unilateral and 140 bilateral Undetectable AMH in 30%, low in 21%, and normal in 49%
(40) 105 Polish 1–4 years Unilateral Mean AMH not statistically different from controls
Gene polymorphisms in cryptorchid boys, no association with AMH levels
(41) 104 Australian 0–18 years 76 unilateral and 28 bilateral Lower mean AMH in bilateral cryptorchid as compared with unilateral and 
controls
(38) 94 Danish 0.5–13.1 years 
(prepubertal)
53 unilateral and 41 bilateral Decreased in 5% (no distinction made between unilateral and bilateral)
(25) 65 USA 2 days–11 years Bilateral non-palpable Undetectable AMH in anorchid, low AMH in 14 cryptorchid with 
histological damage, normal AMH in 34 with histologically normal testes
(42) 50 Polish 1–4 years Unilateral Mean AMH not statistically different before and after orchiopexy
(37) 50 Polish 1–4 years Unilateral Lower mean AMH in cryptorchid as compared with controls
(36) 43 Various 85 ± 31 days N.S. Mean AMH not statistically different from controls
(43) 31 Brazilian 0.75–9 years 24 unilateral and 7 bilateral Mean AMH within normal range
(44) 27 French 14–32 months 17 unilateral and 10 bilateral Lower mean AMH in bilateral but not unilateral cryptorchid as compared 
with controls
(35) 20 Turkish 12 months 20 unilateral Lower mean AMH in cryptorchid as compared with controls
(45) 18 N.S. 0.6–6.1 years N.S. No differential AMH mRNA levels reported between patients with high risk 
and those with low risk for azoospermia
(34) 15 French 1 day–10 years Unilateral and bilateral Decreased in 75% (no distinction made between unilateral and bilateral)
(46) 15 N.S. 7–55 months 7 unilateral and 8 bilateral No changes reported in AMH mRNA levels in testicular biopsy
N.S., not specified; AMH, anti-Müllerian hormone.
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 10.8 Supplementary Table 1. 
Serum AMH levels in normal controls (same as Table 2) and in patients with cryptorchidism without micropenis. 
 
 1 - 5.9 months  6 months - 1.9 yr  2 - 8.9 yr  ≥ 9 yr 
  Controls Unilateral Bilateral  Controls Unilateral Bilateral  Controls Unilateral Bilateral  Controls Unilateral Bilateral 
AMH*                
n 24 11 6  26 28 47  95 67 90  34 15 21 
Median (pmol/L) 697 942 1179  1132 981 684  684 685 553  713 552 580 
Range (pmol/L) 418-1939 153-1337 529-1417  441-2682 405-2061 172-1747  207-2761 117-1635 35-1400  256-1462 299-966 43-1175 
< 3rd centile, n(%)  1 (9.3) 0   2 (7.1) 14 (29.8)   4 (6.0) 12 (13.3)   0 2 (9.5) 
Kruskal Wallis + Dunn ** a a a  a a b  a a b  a a a 
                
* To obtain serum AMH in ng⁄mL, divide by 7.14. 
** Kruskal–Wallis test followed by Dunn’s multiple comparison test (Controls vs Unilateral vs Bilateral). In each age subgroup, a different letter indicates that 
there is a significant difference when comparing Controls vs Unilateral vs Bilateral (P<0.05). 
 
